Skip to main content

Lifting Lids: Update on the Medical Treatment of Acquired Blepharoptosis - Wednesday, May 26, 2021

CME Webinar

Wednesday, May 26, 2021
4:30 PM PST | 5:30 PM MST| 6:30 PM CST| 7:30 PM EST


NOTE: You will be asked to "sign in" or "sign up" to register for the program and then complete a brief pretest. Once you submit your answers, choose "next item". Upon registration, a link to access the webinar will be sent in a confirmation email.

Please contact with any questions. Thank you!

Wendy W. Lee, MD, MS (Chair)
Professor of Clinical Ophthalmology and Dermatology
Oculofacial Plastic & Reconstructive Surgery, Orbit, and Oncology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, Florida

Andrew R. Harrison, MD
Associate Professor
Department of Ophthalmology and Visual Neurosciences
Associate Professor
Department of Otolaryngology, Head and Neck Surgery
Director, Ophthalmic Plastic and Reconstructive Surgery Service
Co-Director, Center for Thyroid Eye Disease
University of Minnesota
Minneapolis, Minnesota


Target Audience
This educational activity is intended for ophthalmologists.

Learning Objectives
After completing this activity, participants will be better able to:
  • Describe the pathophysiology of blepharoptosis
  • Review clinical data on the pharmacologic treatment options for blepharoptosis
  • Identify the appropriate treatment course for a variety of patients with acquired blepharoptosis

Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
MedEdicus LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Obtaining Credit
To obtain AMA PRA Category 1 Credit™ for this activity, participate in the webinar, consult referenced sources as necessary, and complete the posttest and evaluation online. After completing the posttest and evaluation, a certificate will be made available immediately.

Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.

Andrew R. Harrison, MD, is a consultant for Horizon Therapeutics plc and Osmotica Pharmaceuticals plc.

Wendy W. Lee, MD, MS,
is a consultant for Allergan, Bausch & Lomb Incorporated; Galderma, Horizon Therapeutics plc, Mallinckrodt, Osmotica Pharmaceuticals plc, and Revance Therapeutics, Inc.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners and Managers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from RVL Pharmaceuticals, Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or RVL Pharmaceuticals, Inc.

This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 240